Inflammatory polyneuropathies are present in clinical practice as a heterogeneous group of diseases, not only in terms of clinical symptoms, but also in terms of their therapeutic response. Reliable biomarkers are lacking both for diagnostics and as markers of response to specific therapies. This is primarily due to the fact that the pathogenesis of the immunneuropathies is still largely unexplained. T cell-mediated, auto-antibody-induced, complement-mediated damage mechanisms as well as a damaged blood-nerve barrier are discussed as possible causes of autoimmune-inflammatory neuropathies [1]. Therefore, immuno-neuropathies, in particular the chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), are not only clinically but also pathophysiologically a heterogeneous disease group. A subform of the CIDP are e. g., ganglioside autoantibody neuropathies, which account for only a few percent of the CIDP cases but, depending on the antigen, exhibit characteristic disease patterns [2]. In recent years, a further subform of autoantibody-associated neuropathies has been identified: immuno-neuropathies with autoantibodies against paranodal proteins [3].

The node of Ranvier – more than just a gap in the Myelin Sheath

Paranodium is the portion of the nerve fiber directly adjoining the sides of the node of Ranvier. It demarcates the node, on which the sodium channels important for the saltatorial excitation are localized, from the juxtaparanode, where potassium channels are located [4]. The myelin sheath is connected to the axon via a complex of the paranodal proteins neurofascin-155, contactin-1 and caspr-1 (Fig. 1). This complex serves, for example, as diffusion barrier for ion channels [5]. It has been described in various studies [6–10] that especially in the case of demyelinating neuropathies, changes in the node of Ranvier architecture can occur. It has been known for a long time that, in the case of primarily demyelinating polyneuropathies, segmental demyelination begins with an elongation of the node and extends in the direction of internodes, and a decrease in node length occurs again during remyelination [11–13]. Recently, however, proteins of the node of Ranvier have been identified as antigens for inflammatory neuropathies [14–18].

**ABSTRACT**

Autoimmune neuropathies with autoantibodies against paranodal proteins have been described in the last few years. They comprise a subgroup of inflammatory neuropathies with IgG4 autoantibodies against the paranodal proteins neurofascin-155, contactin-1 and caspr-1. Although this subtype of autoimmune neuropathy represents less than 10% of all patients diagnosed with CIDP, it is of high interest as they show a different response to treatment. Even though there are no therapeutic studies available due to the limited number of patients identified so far, all case reports published so far report an excellent response to treatment with rituximab, and in most cases no response to treatment with IVIG, the standard therapy of CIDP. The typical clinical picture of patients with autoantibodies against paranodal proteins is characterized by an acute onset of a severe predominantly motor neuropathy, often accompanied by action tremor and sensory ataxia, with demyelinating features in the nerve conduction studies but an axonal histological phenotype. The latter may be explained by the pathogenetic concept of a paranodopathy/nodopathy, a disease of the paranode/node of Ranvier.

**Neurofascin-155 Autoantibodies**

Autoantibodies to neurofascin-155 were first described in multiple sclerosis, since neurofascin-155 is also present in paranodes of the CNS [19]. The extent to which these contribute to the pathogenesis of multiple sclerosis as part of the humoral immune response has not yet been finally clarified. In 2012, Ng et al. showed the presence of autoantibodies against neurofascin-155 (the paranodal isoform) and ~ 186 (the nodally localized isoform) in 4% of patients with Guillain-Barré syndrome and CIDP using ELISA and cell-based assay [17].
Although the 2 isoforms differ only slightly, isotype-specific autoantibodies are present in almost all patients [17]. A uniform clinical phenotype, consisting of severe motor symptoms, acute onset, poor response to intravenous immunoglobulins (IVIG) and cerebellar tremor, was reported by Querol et al. [20]. This clinical phenotype was confirmed in follow-up studies [21, 22]. Neurofascin-155 autoantibodies have also been described in patients with CIDP in combination with a central involvement, but there are contradictory findings with regard to a preferential occurrence of neurofascin-155 autoantibodies in this subgroup [23, 24]. The prevalence of neurofascin-155 autoantibodies in patients with CIDP was approximately 4% [20] in a European cohort, 3% in a cohort with Japanese and European patients, and 7% in Japanese cohorts [21] and 18% [22]. The extent to which ethnic differences and a different sensitivity and specificity of the different assays play a role currently cannot be determined with certainty. However, it can be assumed that neurofascin-155 autoantibodies occur in a subgroup of patients diagnosed with a CIDP and are associated with a characteristic phenotype.

Contactin-1 Autoantibody

In 2013, Querol et al. detected autoantibodies to contactin-1 in 2 patients with CIDP, and autoantibodies to the protein complex of contactin-1 and Caspr in a further patient [16]. Clinically, the patients were characterized by acute onset severe polyneuropathy, predominantly motor in character. A study carried out in our clinic found that in 3 out of 4 patients identified with contactin-1 autoantibodies also exhibited intention tremor [25] whereas in a Japanese cohort, sensory ataxia was clinically important [26]. The prevalence in the cohorts studied so far is 2.4–7.5% [16, 25, 26].

Caspr-1 Autoantibody

We recently identified in our cohort of patients with inflammatory neuropathies autoantibodies to the third paranodal protein Caspr-1 [27]. While neurofascin-155 and contactin-1 autoantibodies were almost exclusively detectable in patients with chronic inflammatory polyneuropathy, Caspr-1 autoantibodies were detected in a patient with Guillain-Barré syndrome and a patient with CIDP. Both exhibited severe, acutely onset polyneuropathy, predominantly motor, and with pronounced neuropathic pain. The prevalence in our cohort was 3.5%, but both prevalence and clinical phenotype must be confirmed in further studies (▶Table 1).

Assays for the detection of autoantibodies to paranodal proteins

So far, various assays have been used for the detection of autoantibodies to paranodal proteins. The ELISA was predominantly used as a screening instrument [17, 25, 26]. However, the selection of the protein has to be taken into account: For neurofascin-155 it has been shown in several studies that the use of neurofascin-155-NS0 of the rat can result in a nonspecific binding [17, 28, 29]. Therefore, coating the ELISA plates with human neurofascin-155 is recommended. Another frequently used test is the binding experiment with HEK293 cells transfected with the DNA of the respective antigen, also in combination with flow cytometry for quantification [16, 17, 27]. For detection of the paranodal binding, binding assays were carried out with murine teased fibers in almost all studies [16, 20, 25, 27]. Thus, although with these experiments the specific antigen cannot be determined, a paranodal binding can be demonstrated. Western blot was only used in a few studies and showed false-negative results in individual patients, possibly due

▶Table 1 Overview of the characteristics of each autoantibody against paranodal proteins.

<table>
<thead>
<tr>
<th></th>
<th>Neurofascin-155</th>
<th>Contactin-1</th>
<th>Caspr-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prevalence in CIDP</td>
<td>3–18%</td>
<td>2.4–7.5%</td>
<td>ca. 3%</td>
</tr>
<tr>
<td>Literature</td>
<td>Ng et al., 2012, Kawamura et al., 2013, Querol et al., 2014, Ogata et al., 2015, Devaux et al., 2016</td>
<td>Querol et al., 2013, Doppler et al., 2015, Miura et al., 2015</td>
<td>Doppler et al., 2016</td>
</tr>
<tr>
<td>Clinical phenotype</td>
<td>Acute onset</td>
<td>Acute onset</td>
<td>Acute onset</td>
</tr>
<tr>
<td></td>
<td>Motor &gt; sensory</td>
<td>Motor &gt; sensory</td>
<td>Motor &gt; sensory</td>
</tr>
<tr>
<td></td>
<td>Cerebellar tremor</td>
<td>(Intention tremor)</td>
<td>Neuropathic pain</td>
</tr>
<tr>
<td>IgG-Subclasses</td>
<td>IgG4 &gt; IgG3 &gt; IgG1</td>
<td>IgG4 &gt; IgG3</td>
<td>IgG4</td>
</tr>
</tbody>
</table>
to the denaturation of the protein [25, 29]. In summary, the ELISA appears to be a reliable screening tool, and binding experiments with transfected HEK293 cells, or directly with the nerve tissue, are suitable as confirmatory tests.

Pathophysiology: Concept of Paranodopathy

Although neuropathies with autoantibodies to paranodal proteins are classified as subtypes of CIDP, it is not a classical demyelinating polyneuropathy. In contrast to the CIDP, in nerve biopsies, there are no signs of demyelination/remyelination, such as onion bulb formations or thinly myelinated fibers (22,25,27). This is because the myelin sheath is not the point of attack of the autoantibodies. Electrophysiologically, there are conduction blocks, prolonged F-latencies and distal motor latencies, and reduced nerve conduction velocity, so that the electrophysiological criteria of a CIDP are usually met [16, 20, 25, 27]. This apparent discrepancy between histology and electrophysiology is explained by the concept of paranodopathy/nodopathy, a disease targeting the complex nodal region [30, 31]. The hypothesis is that the autoantibodies interfere with the adhesion of the paranodal proteins and thus interfere with the connection between axon and myelin sheath, which could lead to elongation of the nerve and dispersion of ion channels at the node of Ranvier of the elongated nerve. Thus, the presence of conduction blocks and the extended distal motor latency can be explained by the lengthening of the myelin sheath gaps as well as the reduced nerve conduction velocity [31]. In fact, it was shown in vitro that autoantibodies to contactin-1 inhibit the adhesion of the paranodal proteins and lead to the destruction of their architecture [32]. The latter was confirmed in skin nerves and nerve teased nerve fibers of patients with contactin-1, Caspr-1, and neurofascin-155-associated neuropathy [22, 25, 27] (Fig. 2).
Role of IgG subclasses

In the majority of cases, autoantibodies to paranodal proteins are immunoglobulins of subclass IgG4 [17, 20, 25–27]. This has a special role among the immunoglobulins in that it does not activate complement and is predominantly functionally monovalent and thus does not lead to cross-linking of antigens [33, 34]. Therefore, in the majority of patients, one cannot assume the presence of a complement-mediated inflammatory reaction, which is pathogenically relevant in neuropathies with ganglioside autoantibodies. A possible pathophysiological mechanism, however, is antibody binding-induced transformational processes in the node of Ranvier, as described above. It is assumed that the lack of efficacy for IVIG in these patients is associated with the lack of complement activation [20]. It is known that IVIG inhibits complement activation even if the exact mode of IVIG action is still not elucidated in detail [35, 36]. However, not all autoantibodies to paranodal proteins belong to the IgG4 subclass. Patients with contactin-1 and Caspr autoantibodies with IgG3 predominance have also been described. Also, most patients with predominant IgG4 autoantibodies are by no means exclusively IgG4. Thus, it was shown that sera from patients with predominant IgG4 lead to a complement binding, presumably by IgG3, though not abundantly present [37]. The extent to which IgG3 autoantibodies are pathogenic remains to be clarified in vivo. For IgG4 autoantibodies to contactin-1, a potential pathogenicity has already been demonstrated in the passive transfer model, but not yet for IgG3 [38]. The cause for the presence of different IgG subclasses with the same antigen is not yet known.

Therapy of neuropathy with antibodies to paranodal antibodies

The number of patients known to have autoantibodies to paranodal proteins is just as small as the number of studies. It is not surprising that there are no studies as yet on therapeutic strategies. However, in the available case reports, impressive and uniform response to rituximab of patients with IgG4 autoantibodies against neurofascin-155, contactin-1 and Caspr is described [25, 27, 39]. A temporary response to corticosteroids and plasmapheresis has also also been reported, and occasionally in patients with IgG3 autoantibodies also response to IVIG [25, 27, 37]. However, the clearest and most sustained improvement is seen after administration of rituximab, so that in patients with IgG4 autoantibodies to paranodal antigens, contrary to the guidelines for CIDP therapy, this can well be the first choice drug. The extent to which this is also true of the rare occurrence of predominantly IgG3 autoantibodies to paranodal proteins cannot as yet be estimated. In patients with relatively acute onset of predominantly motor inflammatory neuropathy, the presence of autoantibodies to paranodal proteins should be suspected, especially in the case of poor response to IVIG. If there is evidence for the presence of autoantibody, given available evidence, we consider initiation of therapy with rituximab as reasonable.

Commercial tests for the detection of autoantibodies to paranodal proteins are not currently available, but research labs (for example, Würzburg University Hospital, Neurology) can help demonstrate the presence of these antibodies.

Conclusion

Neuropathies with autoantibodies to paranodal proteins are a new subgroup of immune neuropathies. The characteristic clinical picture is a relatively acute onset of severe motor neuropathy, partly together with cerebellar tremor. The autoantibodies predominantly belong to the subclass IgG4 and patients typically respond well to therapy with rituximab but most often not to IVIG.

Conflict of interest

The authors declare no conflict of interest.

References


[34] Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol 2014; 5: 520


[36] Piepers S, Jansen MD, Cats EA et al. IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN. J Neuroimmunol 2010; 229: 256–262


